Keyword: Cigna

Top PBM Express Scripts said that its efforts saved clients $45 billion in 2018, and its clients' drug costs grew just 0.4% last year.

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.

In the wake of the Aetna-CVS combo, Cigna's Express Scripts buy could mean more pricing resistance ahead for drugmakers.

Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.

On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim.

Mylan is taking another hit tied to its EpiPen pricing controversy.

Harvard Pilgrim broke new ground in the pay-for-performance arena, striking a first-ever deal for Eli Lilly's diabetes med Trulicity and the latest outcomes-based arrangement on Novartis' Entresto.

Pharma may have pulled off only a few outcomes-based pricing deals with payers, but companies are likely to add more to that list soon--many more, if payers have their way.

Pay-for-performance is catching on. With a results-based reimbursement deal on Novartis' Entresto under its belt, Cigna has struck similar pacts on pricey cholesterol fighters from Amgen, Sanofi and Regeneron.